Literature DB >> 32354931

A Simple Implement for Assessing the Survival of Elderly Patients With Melanoma Irradiated for Cerebral Metastases.

Trang Nguyen1, Stefan Janssen1,2, Steven E Schild3, Dirk Rades4.   

Abstract

BACKGROUND/AIM: Secondary brain lesions occur commonly in patients with advanced melanoma. Despite increasing use of local therapies, many elderly patients qualify for whole-brain radiotherapy (WBRT). For these patients, a survival score was created. PATIENTS AND METHODS: Seven characteristics were retrospectively investigated in 35 elderly (≥65 years) patients with melanoma, namely WBRT regimen, age, gender, Karnofsky performance score (KPS), number of brain lesions, non-cerebral metastases and interval from melanoma diagnosis to WBRT.
RESULTS: Age ≤71 years (p=0.044) and KPS ≥80% (p=0.005) were significantly associated with more favorable survival. Based on these characteristics, patients received 0 (n=13), 1 (n=12) or 2 points (n=10). Two prognostic groups were designed, 0 or 1 point vs. 2 points, with actuarial 6-month survival rates of 12% and 48%, respectively (p=0.002).
CONCLUSION: This simple implement allows quick estimation of the survival of elderly patients receiving WBRT for cerebral metastases from melanoma. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Melanoma; cerebral metastases; elderly patients; prognostic tool; survival; whole-brain radiotherapy

Mesh:

Year:  2020        PMID: 32354931      PMCID: PMC7279822          DOI: 10.21873/invivo.11914

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  16 in total

1.  Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma.

Authors:  Lena Sehmisch; Stefan Huttenlocher; Steven E Schild; Dirk Rades
Journal:  J Dermatol       Date:  2014-08-25       Impact factor: 4.005

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 3.  New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.

Authors:  Kaamar Azijli; Ellen Stelloo; Godefridus J Peters; Alfons J M VAN DEN Eertwegh
Journal:  Anticancer Res       Date:  2014-04       Impact factor: 2.480

4.  Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM.

Authors:  Dirk Rades; Lena Sehmisch; Heinke C Hansen; Liesa Dziggel; Stefan Janssen; Steven E Schild
Journal:  Anticancer Res       Date:  2019-03       Impact factor: 2.480

5.  Development of a Survival Score for Patients with Cerebral Metastases from Melanoma.

Authors:  Lena Sehmisch; Steven E Schild; Dirk Rades
Journal:  Anticancer Res       Date:  2017-01       Impact factor: 2.480

6.  Prognostic Factors After Whole-brain Radiotherapy Alone for Brain Metastases from Malignant Melanoma.

Authors:  Dirk Rades; Lena Sehmisch; Stefan Janssen; Steven E Schild
Journal:  Anticancer Res       Date:  2016-12       Impact factor: 2.480

7.  Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis.

Authors:  Dirk Rades; Annika Panzner; Liesa Dziggel; Tiina Haatanen; Radka Lohynska; Steven E Schild
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

8.  A Specific Survival Score for Patients Receiving Local Therapy for Single Brain Metastasis from a Gynecological Malignancy.

Authors:  Dirk Rades; Liesa Dziggel; Steven E Schild
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

9.  A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone.

Authors:  Stefan Huttenlocher; Liesa Dziggel; Dagmar Hornung; Oliver Blanck; Steven E Schild; Dirk Rades
Journal:  Radiat Oncol       Date:  2014-09-20       Impact factor: 3.481

10.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Authors:  Paula Mulvenna; Matthew Nankivell; Rachael Barton; Corinne Faivre-Finn; Paula Wilson; Elaine McColl; Barbara Moore; Iona Brisbane; David Ardron; Tanya Holt; Sally Morgan; Caroline Lee; Kathryn Waite; Neil Bayman; Cheryl Pugh; Benjamin Sydes; Richard Stephens; Mahesh K Parmar; Ruth E Langley
Journal:  Lancet       Date:  2016-09-04       Impact factor: 79.321

View more
  1 in total

1.  Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery.

Authors:  Carsten Nieder; Bård Mannsåker; Rosalba Yobuta
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.